je.st
news
Changes to late-stage breast cancer trial sends shares of Celldex plunging
2014-11-06 01:48:08| Biotech - Topix.net
It wasn't the financial picture at Celldex Therapeutics that sent investors running today. Rather, it was the news that a trial of one its two lead cancer drugs will last longer than hoped that sent its shares down 20 percent as of 2 p.m. today.
Tags: trial
cancer
shares
breast
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||